Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients
Double-Blind Placebo-Controlled Study of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients
Sponsor: Stallergenes Greer
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Stallergenes Greer
Listed as NCT00410930, this PHASE2 trial focuses on Allergy and remains terminated or withdrawn. Sponsored by Stallergenes Greer, it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE2
First recorded
Nov 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Stallergenes Greer
For direct contact, visit the study record on ClinicalTrials.gov .